直播预告 | 靶向血液蛋白质组-助力精准医学线上研讨会

Prior to joining SomaLogic, Dr. Janjic was the Founder and CSO of Replidyne, Inc., a biotechnology company focusing on the development of novel small-molecule antibacterial agents. He currently serves as an advisor and Chairman of the Board of Crestone, Inc., the successor company of Replidyne. Prior to Replidyne, he was among the initial group of scientists to join NeXagen, which later became NeXstar Pharmaceuticals. As the Senior Director of Drug Discovery at NeXstar, he was responsible for creating a pipeline of aptamer-based drug candidates for pre-clinical and clinical development. His contributions included the discovery and early development of Macugen, a first-in-class, FDA-approved treatment for macular degeneration that was named Innovative Pharmaceutical Product of the Year in 2005. Dr. Janjic received his bachelor’s degree in molecular biology and doctorate in physical organic chemistry from the University of Washington in Seattle. He completed his postdoctoral training at the Scripps Research Institute in La Jolla as a Cancer Research Institute Fellow.

多年来专注于蛋白组学研究，曾参与多项国家重点基金项目、国家自然科学基金和科技创新基金等工作，具有丰富的方案设计、项目管理和技术支持等工作经验。目前主要负责蛋白组学产品的开发和技术支持工作。